Phase 2, Double-Blind, Placebo-Controlled Trial of Bupropion for Methamphetamine Dependence
NCT ID: NCT00687713
Last Updated: 2017-03-21
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
200 participants
INTERVENTIONAL
2008-05-31
2011-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Bupropion for the Treatment of Methamphetamine Dependence - 1
NCT00069251
Effectiveness of Bupropion Combined With Behavioral Therapy for Treating Methamphetamine Dependence - 2
NCT00135785
Assessment of Potential Interactions Between Methamphetamine and Bupropion - 1
NCT00040040
Phase 2, Multi-Center Trial of Modafinil for Methamphetamine Dependence
NCT00520286
Study of Medical Treatment for Methamphetamine Addiction
NCT00833443
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
It is hypothesized that bupropion, compared to placebo, would be associated with an increase in the proportion of subjects who achieved abstinence (confirmed by at least two methamphetamine-negative urines and no methamphetaminepositive urines) each week during the last two weeks (Weeks 11 and 12) for non-daily users.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Bupropion
Subjects will receive bupropion 150 mg tablet for 3 days then twice daily, for 12 weeks until dose taper during the last 3 days of week 12 at 150 mg per day.
Bupropion
150mg for the first 3 days of dosing. Increased to 150 mg b.i.d until taper.
Placebo
Subjects will receive a matched bupropion placebo 150 mg tablet for 3 days then twice daily, for 12 weeks until dose taper during the last 3 days of week 12 at 150 mg per day.
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bupropion
150mg for the first 3 days of dosing. Increased to 150 mg b.i.d until taper.
Placebo
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must have at least 1 amphetamine or methamphetamine positive urine specimen after the start of screening and before randomization or provide information to verify recent use if a positive urine sample can't be obtained
* Must report using methamphetamine for 29 days or less during the 30 day period prior signing consent using the timeline follow-back method
* Must be willing and able to comply with study procedures
* Must be able to verbalize and understand consent forms and provide written informed consent
* Must be seeking treatment for methamphetamine dependence
Exclusion Criteria
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Drug Abuse (NIDA)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jurij Mojsiak
Role: STUDY_CHAIR
National Institute on Drug Abuse (NIDA)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UCLA Integrated Substance Abuse Program
Los Angeles, California, United States
South Bay Treatment Center
San Diego, California, United States
Addiction and Pharmacology Research Laboratory
San Francisco, California, United States
Friends Research Institute
Torrance, California, United States
Matrix Institute
Woodland Hills, California, United States
Pacific Addiction Research Center - U of Hawaii
Honolulu, Hawaii, United States
Iowa Luther Hospital
Des Moines, Iowa, United States
U of Kansas Medical Center
Kansas City, Missouri, United States
New York University
New York, New York, United States
Medical University of South Carolina
Charleston, South Carolina, United States
University of Texas Health Science At San Antonio
San Antonio, Texas, United States
VA Salt Lake City Health Care System
Salt Lake City, Utah, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Anderson AL, Li SH, Markova D, Holmes TH, Chiang N, Kahn R, Campbell J, Dickerson DL, Galloway GP, Haning W, Roache JD, Stock C, Elkashef AM. Bupropion for the treatment of methamphetamine dependence in non-daily users: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend. 2015 May 1;150:170-4. doi: 10.1016/j.drugalcdep.2015.01.036. Epub 2015 Feb 7.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MDS Bupropion Meth 0001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.